TG Therapeutics, Inc. (NASDAQ:TGTX) Given Average Rating of “Moderate Buy” by Brokerages

Shares of TG Therapeutics, Inc. (NASDAQ:TGTX) have been assigned a consensus recommendation of “Moderate Buy” from the nine analysts that are currently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, three have given a hold recommendation, four have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $53.3333.

Several equities analysts have issued reports on TGTX shares. Bank of America boosted their target price on TG Therapeutics from $17.00 to $20.00 and gave the stock an “underperform” rating in a research report on Tuesday, July 7th. Weiss Ratings raised TG Therapeutics from a “hold (c)” rating to a “hold (c+)” rating in a report on Friday, May 1st. HC Wainwright lifted their price target on TG Therapeutics from $70.00 to $77.00 and gave the company a “buy” rating in a research note on Monday. Jefferies Financial Group reaffirmed a “buy” rating and set a $83.00 price objective on shares of TG Therapeutics in a report on Monday, June 22nd. Finally, Zacks Research upgraded TG Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, June 1st.

Hedge Funds Weigh In On TG Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Danske Bank A S purchased a new position in shares of TG Therapeutics in the 3rd quarter valued at about $25,000. EverSource Wealth Advisors LLC boosted its holdings in TG Therapeutics by 51.9% during the first quarter. EverSource Wealth Advisors LLC now owns 1,068 shares of the biopharmaceutical company’s stock worth $35,000 after buying an additional 365 shares in the last quarter. Hantz Financial Services Inc. boosted its holdings in TG Therapeutics by 82.7% during the fourth quarter. Hantz Financial Services Inc. now owns 1,237 shares of the biopharmaceutical company’s stock worth $37,000 after buying an additional 560 shares in the last quarter. Truvestments Capital LLC boosted its holdings in TG Therapeutics by 172.4% during the fourth quarter. Truvestments Capital LLC now owns 1,621 shares of the biopharmaceutical company’s stock worth $48,000 after buying an additional 1,026 shares in the last quarter. Finally, Kemnay Advisory Services Inc. acquired a new position in TG Therapeutics during the fourth quarter worth about $52,000. 58.58% of the stock is owned by institutional investors and hedge funds.

TG Therapeutics Trading Down 3.7%

Shares of TG Therapeutics stock opened at $55.01 on Tuesday. TG Therapeutics has a 52-week low of $25.28 and a 52-week high of $59.30. The company has a quick ratio of 5.12, a current ratio of 5.81 and a debt-to-equity ratio of 1.28. The company’s 50-day simple moving average is $46.60 and its 200-day simple moving average is $36.52. The firm has a market cap of $8.42 billion, a price-to-earnings ratio of 19.23, a price-to-earnings-growth ratio of 1.38 and a beta of 1.60.

TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings results on Wednesday, May 6th. The biopharmaceutical company reported $0.12 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.23 by ($0.11). The firm had revenue of $204.92 million for the quarter, compared to analysts’ expectations of $200.33 million. TG Therapeutics had a return on equity of 88.73% and a net margin of 65.95%.The company’s revenue for the quarter was up 69.5% on a year-over-year basis. During the same period in the prior year, the company earned $0.03 earnings per share. As a group, equities research analysts anticipate that TG Therapeutics will post 1.51 earnings per share for the current year.

About TG Therapeutics

TG Therapeutics, Inc is a clinical?stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small?molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.